A comparison of intravaginal PGF2 alpha and intravenous XXXX to stimulate labour after membrane rupture.

@entity1 @entity398 @entity4837 @entity1337 @entity6882 @entity3774
A prospective randomized controlled trial of 202 @entity1 was set up to examine the efficiency and safety of 40 mg of intravaginal @entity3774 (PGF2 alpha) in a tylose gel to stimulate labour after artificial or spontaneous membrane rupture. The control group received a standard intravenous @entity398 regimen. The PGF2 alpha treated group had a significantly shorter length of labour (6.2 +/- 3.6 hours) compared to the @entity398 group (7.5 +/- 4.3 hours) (p less than 0.05). The analgesic requirements were significantly reduced in the PGF2 alpha treated @entity1 . In PGF2 alpha treated @entity1 46 of 105 required no @entity1337 whereas 17 of 97 @entity398 treated @entity1 required no @entity1337 (p less than 0.001). There were similar reductions for epidural (p less than 0.005) and @entity6882 requirements (p less than 0.005). No differences were found between groups with regards mode of delivery. There were no adverse maternal side-effects associated with PGF2 alpha usage. A significant reduction (p less than 0.05) in the incidence of @entity4837 requiring phototherapy occurred in the PGF2 alpha group. @entity3774 appears to be a safe, efficient and better alternative to intravenous @entity398 to stimulate labour in the presence of ruptured membranes, allowing ambulation, a reduction in length of labour and less need for @entity1337 and intravenous therapy.
